# Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)

> **NCT03358576** · PHASE3 · COMPLETED · sponsor: **Iterum Therapeutics, International Limited** · enrollment: 674 (actual)

## Conditions studied

- Intra Abdominal Infections

## Interventions

- **DRUG:** Ertapenem
- **DRUG:** Sulopenem-Etzadroxil/Probenecid
- **DRUG:** Ciprofloxacin
- **DRUG:** Metronidazole
- **DRUG:** Amoxicillin-Clavulanate
- **DRUG:** Sulopenem

## Key facts

- **NCT ID:** NCT03358576
- **Lead sponsor:** Iterum Therapeutics, International Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-18
- **Primary completion:** 2019-10-02
- **Final completion:** 2019-10-02
- **Target enrollment:** 674 (ACTUAL)
- **Last updated:** 2020-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03358576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03358576, "Sulopenem Versus Ertapenem for Complicated Intra-abdominal Infection (cIAI)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03358576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*